Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
November 20, 2015
Geneva, Switzerland, 20 November 2015 – ObsEva and Kissei Pharmaceutical Co., Ltd. (“Kissei”) today announced that they have entered into a…
Read morepress release
November 4, 2015
Geneva, Switzerland, 04 November 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
Read morepress release
September 22, 2015
Geneva, Switzerland, 22 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
Read moreMay 28, 2021
June 9, 2020
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840